Psychosocial factors affecting medication adherence among HIV-1 infected adults receiving combination antiretroviral therapy (cART) in Botswana

AIDS Research and Human Retroviruses

Volumn 26, Issue 6, 2010, Pages 685-691

  Do, Natalie T ^a   Phiri, Kelesitse ^b   Bussmann, Hermann ^a,b   Gaolathe, Tendani ^a,c   Marlink, Richard G ^a,b   Wester, C William ^a,b,d,e  

^a BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Department of HIV AIDS Prevention and Care   (Botswana)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BOTSWANA; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG USE; FEMALE; HEALTH BELIEF; HEALTH CARE PERSONNEL; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KARNOFSKY PERFORMANCE STATUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; NAUSEA; PATIENT ATTITUDE; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF REPORT; SOCIAL PSYCHOLOGY; VOMITING; ADOLESCENT; HIV INFECTIONS; MEDICATION COMPLIANCE; PROCEDURES; PSYCHOLOGY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BOTSWANA; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; PSYCHOLOGY; QUESTIONNAIRES; YOUNG ADULT;

EID: 77954196309     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0222     Document Type: Article

References (39)

1. UNAIDS 2008 Report on the global AIDS epidemic, 2008; data.unaids.org=pub=GlobalReport=2008=jc1510-2008-global- report- en.pdf; accessed 17 January 2009.
2. -2005 Botswana National HIV-1 Sentinel Surveillance report, Ministry of Health, Gaborone, Botswana.
3. Erwin J: Adherence and its implications for antiretroviral therapy. Int Antiviral News 1998;6:12-14.
4. Hogg RS, Heath K, Bangsberg D, et al.: Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002;16:1051-1058.
5. Stephenson J: AIDS researchers target poor adherence. JAMA 1999;281:1069.
6. Lange J: Issues for the future of antiretroviral therapy. Antiviral Ther 1997;2 (Suppl):71-83.
7. Williams A and Friedland G: Adherence, compliance, and HAART. AIDS Clin Care 1997;7:51-58.
8. Veenstra J, Schuurman R, Cornelissen M, et al.: Transmission of zidovudine-resistant HIV-1 following deliberate injection of blood from a patient with AIDS: Characteristics and natural history of the virus. Clin Infect Dis 1995;21:556-560.
9. Smith DL: Patient compliance: An educational mandate. McLean, VA: Norwich Eaton Pharmaceutical, Inc. and Consumer Health Information Corp., 1989.
10. Chesney MA, Ickovics J, Hecht FM, Sikipa G, Rabkin J. Adherence: A necessity for successful HIV combination therapy. AIDS 1999;13(Suppl A):S271-278.
11. Golin C, Liu H, Hayes R, et al.: A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Int Med 2002;17:756-765.
12. Gordillo V, del Amo J, Soriano V, and Gonzalez-Lahoz J: Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999;13:1763-1769.
13. Miller LG, Liu H, Hayes RD, et al.: Knowledge of antiretroviral dosing and adherence: A longitudinal study. Clin Infect Dis 2003;36:514-518. (Pubitemid 36241321)
14. Ickovics JR and Meisler AW: Adherence in AIDS clinical trials: A framework for clinical research and clinical care. J Clin Epidemiol 1997;50(4):385-391.
15. Ware N, Idoko J, Kaaya S, et al.: Explaining adherence success in sub-Saharan Africa: An ethnographic study. PLoS 2009;6(1):0039-0047.
16. Karnofsky DA and Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of Chemotherapeutic Agents (MacLeod CM, ed.). Columbia University Press, New York, 1949, p. 196.
17. Karnofsky D, Abelman W, Craver L, and Burchenal J: The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-656.
18. Schag CC, Heinrich RL, and Ganz PA: Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol 1984;2:187-193.
19. Johnson JA, et al.: Valuation of EuroQOL (EQ-5D) health states in an adult US sample. Pharmacoeconomics 1998;13: 421-433.
20. Kind P: The EuroQol instrument: An index of health-related quality of life. In: Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. (Spilker B, ed.). Lippincott-Raven Publishers, Philadelphia, 1996, pp. 191-201.
21. Sapin C, Fantino B, Nowicki ML, and Kind P: Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Quality Life Outcomes 2004;2:20.
22. Tucker J, Orlando M, et al.: Psychosocial indicators of antiretroviral non-adherence in HIV-positive adults with substance use and mental health problems. Health Psych 2004; 23:363-370.
23. Judd F and Mijch A: Depressive symptoms in patients with HIV infection. Aust NZ J Psychiatry 1996;30:104-109.
24. Beck AT, Ward CH, and Mendelson M: An inventory for measuring depression. Arch Gen Psychiatry 1961;6:561-571.
25. Bangsberg D, Hecht F, Charlebois E, Zolopa AR, et al.: Adherence to protease inhibitors, HIV-1 viral load and development of drug resistance in an indigent population. AIDS 2000;14:357-366.
26. Bangsberg DR, Perry S, Charlebois ED, et al.: Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1-2.
27. Stone V: Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. Clin Infect Dis 2001;33:865-872.
28. Morisky DE, Green LW, and Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24(1):67-74.
29. Shalansky SJ, Levy AR, and Ignaszewski AP: Self-reported Morisky score for identifying non-adherence with cardiovascular medications. Ann Pharmacother 2004;38(9):1363-1368.
30. Anabwani G and Jimbo W, eds. Botswana Guidelines on Antiretroviral Treatment. Botswana Ministry of Health, Gaborone, 2005.
31. Hardon A, Davey S, Gerrits T, et al.: From access to adherence: The challenges of antiretroviral treatment. Studies from Botswana, Tanzania, and Uganda. World Health Organization, Geneva, 2006.
32. Hardon AP, Akurut D, Comoro C, et al.: Hunger, waiting time and transport costs: Time to confront challenges to ART adherence in Africa. AIDS Care 2007;19:658-665.
33. Derlega VJ, Winstead BA, Greene K, et al.: Reasons for HIV disclosure=nondisclosure in close relationships: Testing a model of HIV-disclosure decision making. J Social Clin Psychol 2004;23(6):747-767.
34. Nachega JB, Knowlton AR, Deluca A, et al.: Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults: A qualitative study. J Acquir Immune Defic Syndr 2006(Suppl I):S127-S133.
35. Medley A, Garcia-Moreno C, McGill S, et al.: Rates, barriers, and outcomes of HIV sero-disclosure among women in developing countries: Implications for prevention of motherto- child transmission programmes. Bull WHO 2004;82(4): 299-307.
36. Schuler SR, Hashemi SM, Riley AP, et al.: Credit programs, patriarchy, and men's violence against women in rural Bangladesh. Social Sci Med 1996;43(12):1729-1742.
37. Ying Wu D, et al.: Burden of depression among impoverished HIV positive women in Peru. J Acquir Immune Defic Syndr 2008;48:500-504.
38. Shipton LK, Wester CW, Stock S, et al.: Safety and efficacy of nevirapine and efavirenz based antiretroviral therapy in adults treated for HIV and tuberculosis co-infection in Botswana. Int J Tuberculosis Lung Dis 2009;13(3):360-363.
39. Bisson GP, Gross R, Strom JB, et al.: Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS 2006;20:1613-1619.